Health Condition 1: null- Endometriosis
Conditions
Interventions
Intervention1: Cabergoline: Cabergoline 0.5 mg tablet will be given twice weekly orally for 4 months
Control Intervention1: Leuprolide acetate(GnRH agonists): Leuprolide acetate injection 3.75 mg will
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: 1.Women with a clinical diagnosis with endometriosis by previous laproscopy or USG. 2.Presence of ovarian endometrioma not more than 6cm in diameter. 3.Women do not want to conceive for next 6 months.
Exclusion criteria
Exclusion criteria: 1.Patients with history of any hormonal treatment including contraceptives over past 3 months. 2.Body mass index (BMI) more than 30 kg/m2. 3.Patients with known history of allergy to one of the study medications. 4.Confirmed pregnancy. 5.H/o smoking, tobacco chewing. 6.Presence of hypertension, diabetes mellitus, hyperlipidemia, cardiovascular disease or any inflammatory disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Reduction in VAS score of pain more than 50% in these women. 2.Change in pre and post treatment levels of serum highly purified CRP(hpCRP),TNF-alpha and VEGF.Timepoint: 4 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in Pulse wave velocity of brachial arteryTimepoint: 4 months;Changes in Resistive Index (RI) and Pulsatility Index(PI) of ovarian blood flow.Timepoint: 4 months;Changes in the level of serum CA-125 and serum prolactinTimepoint: 4 months;Reduction in size of Endometrioma as calculated by USG(more than 25% reduction will be taken as effective)Timepoint: 4 months | — |
Countries
India
Contacts
Public ContactDr Neha Jain
AIIMS, New Delhi
Outcome results
None listed